Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

pegcrisantaspase

A recombinant, pegylated form of Erwinia asparaginase (crisantaspase), derived from the bacterium Erwinia chrysanthemi and genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Pegcrisantaspase hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Pegcrisantaspase can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:mPEG-R-crisantaspase
pegylated Erwinia asparaginase
pegylated recombinant L-asparaginase Erwinia chrysanthemi
Foreign brand name:Asparec
Code name:JZP 416
JZP416
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search